Delstrigo 유럽 연합 - 체코어 - EMA (European Medicines Agency)

delstrigo

merck sharp & dohme b.v. - doravirine, lamivudin, tenofovir-disoproxyl-fumarát - hiv infekce - antivirotika pro léčbu infekcí hiv, kombinace - delstrigo je indikován k léčbě dospělých infikovaných hiv-1 bez minulosti nebo současnosti důkazy rezistence vůči nnrti třídy, lamivudin, nebo tenofovir. delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with hiv-1 without past or present evidence of resistance to the nnrti class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.

Invokana 유럽 연합 - 체코어 - EMA (European Medicines Agency)

invokana

janssen-cilag international nv - kanagliflozin - diabetes mellitus, typ 2 - léky užívané při diabetu - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 a 5.

Suliqua 유럽 연합 - 체코어 - EMA (European Medicines Agency)

suliqua

sanofi winthrop industrie - inzulín glargin, lixisenatide - diabetes mellitus, typ 2 - léky užívané při diabetu - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.

Aubagio 유럽 연합 - 체코어 - EMA (European Medicines Agency)

aubagio

sanofi winthrop industrie - teriflunomid - roztroušená skleróza - selektivní imunosupresiva - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Entresto 유럽 연합 - 체코어 - EMA (European Medicines Agency)

entresto

novartis europharm limited - sacubitril, valsartan - srdeční selhání - antagonisté angiotensinu ii, jiné kombinace, látky působící na renin-angiotensinový systém - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

Neparvis 유럽 연합 - 체코어 - EMA (European Medicines Agency)

neparvis

novartis europharm limited - sacubitril, valsartan - srdeční selhání - agens působící na systém renin-angiotenzin - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.

Teriflunomide Mylan 유럽 연합 - 체코어 - EMA (European Medicines Agency)

teriflunomide mylan

mylan pharmaceuticals limited - teriflunomid - roztroušená skleróza, relaps-remitentní - imunosupresiva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Lacosamide Adroiq 유럽 연합 - 체코어 - EMA (European Medicines Agency)

lacosamide adroiq

extrovis eu ltd. - lakosamid - epilepsie - antiepileptika, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Mycapssa 유럽 연합 - 체코어 - EMA (European Medicines Agency)

mycapssa

amryt pharmaceuticals dac - octreotide acetate - acromegalie - hypofýzy a hypotalamické hormony a analogy - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

Apretude 유럽 연합 - 체코어 - EMA (European Medicines Agency)

apretude

viiv healthcare b.v. - cabotegravir - hiv infekce - antivirotika pro systémové použití - apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4. 2, 4. 4 a 5.